17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
14 citations
,
September 1990 in “Journal of the American Academy of Dermatology” Viprostol does not effectively promote hair growth in male pattern baldness.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Blocking Prostaglandin D₂ may help treat hair loss.
January 2006 in “Benzina: Revista d'excepcions culturals” Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
1 citations
,
January 2002 in “PubMed” PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
3 citations
,
December 2024 in “Stem Cell Reports” Low fucosylation boosts stem cell growth in the eye.
April 2017 in “DR-NTU (Nanyang Technological University)” A biodegradable system can deliver finasteride consistently, reducing the need for daily pills.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
October 2025 in “Transplantation” Dissolving microneedles with finasteride improve drug delivery for hair loss treatment.
August 2025 in “International Journal of Pharmaceutics” A new finasteride treatment may quickly and effectively promote hair regrowth.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
April 2018 in “Journal of Investigative Dermatology” A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.
18 citations
,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
6 citations
,
January 2013 in “Experimental dermatology” Bimatoprost increases hair growth in mice without breaking down into other substances.
17 citations
,
March 2004 in “Journal of Investigative Dermatology” Soymetide-4 from soy can prevent hair loss caused by a cancer drug in rats.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
A new topical treatment using micelles shows promise for safer and more effective hair regrowth in androgenetic alopecia.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
123 citations
,
June 2006 in “Journal of Neurobiology” Progesterone protects brain cells, but Provera does not.
3 citations
,
May 2021 in “Archiv der Pharmazie” SUN11602 and ONO-1301 could help in skin healing and creating artificial skin.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
8 citations
,
February 2019 in “Journal of The European Academy of Dermatology and Venereology”